Skip to main content


Cancer Immunology, Immunotherapy

Cancer Immunology, Immunotherapy OnlineFirst articles

27.11.2020 | Research Report

Anti-PD-1 antibody-mediated activation of type 17 T-cells undermines checkpoint blockade therapy

Tumors that develop in the genetic LSL-K-rasG12D murine lung cancer model are resistant to anti-PD-1 antibody treatment. Analysis of tumor-bearing lungs from anti-PD-1-treated mice revealed an up to 2.5-fold increase in IL-17-producing T-cells …

25.11.2020 | Original Article

Let-7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL-13 and IL-10

The microRNA let-7d has been reported to be a tumor suppressor in renal cell carcinoma (RCC). Tumor-associated macrophages (TAM) are M2-polarized macrophages that can enhance tumor growth and angiogenesis in many human cancers. However, the role …

24.11.2020 | Original Article Open Access

Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

Immune checkpoint inhibitors (ICIs) are considered one of the most important breakthroughs in non-small cell lung cancer (NSCLC) treatment considering the impressive efficacy and durable activity achievable in a proportion of patients with …

24.11.2020 | Original Article

Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy

Tumor immunogenicity is driven by various genomic and transcriptomic factors but the association with the overall status of methylation aberrancy is not well established. We analyzed The Cancer Genome Atlas pan-cancer database to investigate …

24.11.2020 | Original Article

Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death; however, a limited number of systemic treatment options for advanced/recurrent HCC exists. Sorafenib or lenvatinib are the only standard systemic treatment …

Aktuelle Ausgaben

Über diese Zeitschrift

Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts.

In addition to publishing original research articles and reviews, CII also offers the following unique publication formats:

  • “Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference.
  • “Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener.

CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).







Weitere Informationen

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.